Methylprednisolone Terminated Phase 2 Trials for Thyroid Eye Disease Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01114503A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease